TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Non-invasive Brain Stimulation on Motor Recuperation
Brief Summary: tDCS (transcranial direct current stimulation) will be used in chronic stroke patients to improve a variety of functions with superior or inferior limb.


Options:
A: Arm Label: Core stability exercises; Type: EXPERIMENTAL; Interventions: Other: Core stability exercises (CSE), Other: Conventional Physiotherapy | Arm Label: Conventional physiotherapy (CP); Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Physiotherapy | Intervention Type: OTHER; Name: Core stability exercises (CSE); Assigned to Arm(s): Core stability exercises | Intervention Type: OTHER; Name: Conventional Physiotherapy; Assigned to Arm(s): Conventional physiotherapy (CP), Core stability exercises
B: Arm Label: Real stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: tDCS (ELDITH) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: tDCS (ELDITH) | Intervention Type: DEVICE; Name: tDCS (ELDITH); Assigned to Arm(s): Real stimulation, Sham
C: Arm Label: Active tDCS+ Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Active tDCS, Other: Physical Therapy | Arm Label: Sham tDCS+Physical Therapy; Type: SHAM_COMPARATOR; Interventions: Other: Physical Therapy, Device: Sham tDCS | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Active tDCS+ Physical Therapy | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): Active tDCS+ Physical Therapy, Sham tDCS+Physical Therapy | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham tDCS+Physical Therapy
D: Arm Label: Early mobilization; Type: EXPERIMENTAL; Interventions: Other: Early mobilization | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early mobilization; Assigned to Arm(s): Early mobilization

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Non-invasive Brain Stimulation on Motor Recuperation
Brief Summary: tDCS (transcranial direct current stimulation) will be used in chronic stroke patients to improve a variety of functions with superior or inferior limb.


Options:
A: Arm Label: SHAM TDCS; Type: SHAM_COMPARATOR; Interventions: Device: Application of Transcranial direct current stimulation (TDCS) | Arm Label: True TDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcranial Direct current stimulation | Intervention Type: DEVICE; Name: Application of Transcranial direct current stimulation (TDCS); Assigned to Arm(s): SHAM TDCS | Intervention Type: DEVICE; Name: Transcranial Direct current stimulation; Assigned to Arm(s): True TDCS
B: Arm Label: Active low-frequency rTMS/sham tDCS; Type: EXPERIMENTAL; Interventions: Device: Repetitive Transcranial Magnetic Stimulation (rTMS), Device: Transcranial Direct Current Stimulation (tDCS) | Arm Label: Active high-frequency rTMS/sham tDCS; Type: EXPERIMENTAL; Interventions: Device: Repetitive Transcranial Magnetic Stimulation (rTMS), Device: Transcranial Direct Current Stimulation (tDCS) | Arm Label: Sham rTMS/active anodal tDCS; Type: EXPERIMENTAL; Interventions: Device: Repetitive Transcranial Magnetic Stimulation (rTMS), Device: Transcranial Direct Current Stimulation (tDCS) | Arm Label: Sham rTMS/active cathodal tDCS; Type: EXPERIMENTAL; Interventions: Device: Repetitive Transcranial Magnetic Stimulation (rTMS), Device: Transcranial Direct Current Stimulation (tDCS) | Arm Label: Sham rTMS/Sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: Repetitive Transcranial Magnetic Stimulation (rTMS), Device: Transcranial Direct Current Stimulation (tDCS) | Intervention Type: DEVICE; Name: Repetitive Transcranial Magnetic Stimulation (rTMS); Assigned to Arm(s): Active high-frequency rTMS/sham tDCS, Active low-frequency rTMS/sham tDCS, Sham rTMS/Sham tDCS, Sham rTMS/active anodal tDCS, Sham rTMS/active cathodal tDCS | Intervention Type: DEVICE; Name: Transcranial Direct Current Stimulation (tDCS); Assigned to Arm(s): Active high-frequency rTMS/sham tDCS, Active low-frequency rTMS/sham tDCS, Sham rTMS/Sham tDCS, Sham rTMS/active anodal tDCS, Sham rTMS/active cathodal tDCS
C: Arm Label: Real stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: tDCS (ELDITH) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: tDCS (ELDITH) | Intervention Type: DEVICE; Name: tDCS (ELDITH); Assigned to Arm(s): Real stimulation, Sham
D: Arm Label: 1- tDCS 2--FES; Type: EXPERIMENTAL; Interventions: Device: Transcranial direct current stimulation (tDCS), Device: Functional electrical stimulation (FES), Device: Sham stimulation | Intervention Type: DEVICE; Name: Transcranial direct current stimulation (tDCS); Assigned to Arm(s): 1- tDCS 2--FES | Intervention Type: DEVICE; Name: Functional electrical stimulation (FES); Assigned to Arm(s): 1- tDCS 2--FES | Intervention Type: DEVICE; Name: Sham stimulation; Assigned to Arm(s): 1- tDCS 2--FES

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX)
Brief Summary: The North Carolina Immunization Branch will evaluate the use of the CDC program to improve adolescent vaccination practices (called Assessment, Feedback, Incentives, and eXchanges, or AFIX). This evaluation is the first of its kind in the nation and may have a profound impact on prevention.

AFIX has four major components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.

This program will evaluate the effectiveness of AFIX visits on affecting provider practices to increase adolescent (age 11-18) immunization. Visits include discussion of that practice's immunization rates and strategies for improving rates. The investigators will compare the changes, from baseline to 5 months, in immunization for practices receiving virtual visits (webinars), in-person visits, and no visits (control group). Thirty practices will be randomly assigned to each intervention type. The main outcomes of this study are practice-wide uptake rates of several adolescent vaccines (Tdap, HPV, and MCV4) as well as pre- and post-AFIX visit surveys focusing on recall tactics utilized by each practice. Data will be collected on practices with at least 200 adolescent patients (note: there is no patient-level data collected in this study).


Options:
A: Arm Label: Education about HPV by school nurse; Type: EXPERIMENTAL; Interventions: Behavioral: Education about HPV by school nurse | Arm Label: Control group 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Education about HPV by school nurse; Assigned to Arm(s): Education about HPV by school nurse
B: Arm Label: Class-based delivery; Type: OTHER; Interventions: Biological: Gardasil® HPV vaccine | Arm Label: Age-based delivery; Type: OTHER; Interventions: Biological: Gardasil® HPV vaccine | Intervention Type: BIOLOGICAL; Name: Gardasil® HPV vaccine; Assigned to Arm(s): Age-based delivery, Class-based delivery
C: Arm Label: Outreach; Type: OTHER; Interventions: Other: outreach services | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: outreach services; Assigned to Arm(s): Outreach
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: AFIX In-Person Visit; Type: EXPERIMENTAL; Interventions: Other: Assessment , Feedback, Incentives, and eXchange Program | Arm Label: AFIX Webinar Visit; Type: EXPERIMENTAL; Interventions: Other: Assessment , Feedback, Incentives, and eXchange Program | Intervention Type: OTHER; Name: Assessment , Feedback, Incentives, and eXchange Program; Assigned to Arm(s): AFIX In-Person Visit, AFIX Webinar Visit

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Brief Summary: Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion (\[MT\] (defined as receiving 10 units or more red blood cells (RBCs) within the first 24 hours). The goal of PROPPR is to improve the basis on which clinicians make decisions about transfusion protocols for massively bleeding patients.

PROPPR is a Resuscitation Outcomes Consortium (ROC) Protocol. ROC is funded by the National Heart, Lung, and Blood Institute (NHLBI), the United States' Department of Defense (DoD) and the Defence Research and Development Canada. PROPPR will be conducted as a Phase III trial at Level I Adult Trauma Centers in North America.


Options:
A: Arm Label: Transfusion Algorithm; Type: OTHER; Interventions: Other: POC-based transfusion algorithm | Intervention Type: OTHER; Name: POC-based transfusion algorithm; Assigned to Arm(s): Transfusion Algorithm
B: Arm Label: 1:1:1 Blood Transfusion Ratio; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1:1:1 Blood Transfusion Ratio | Arm Label: 1:1:2 Blood Transfusion Ratio; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1:1:2 Blood Transfusion Ratio | Intervention Type: BIOLOGICAL; Name: 1:1:1 Blood Transfusion Ratio; Assigned to Arm(s): 1:1:1 Blood Transfusion Ratio | Intervention Type: BIOLOGICAL; Name: 1:1:2 Blood Transfusion Ratio; Assigned to Arm(s): 1:1:2 Blood Transfusion Ratio
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eltrombopag | Intervention Type: DRUG; Name: Eltrombopag; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group A: RiaSTAP; Type: EXPERIMENTAL; Interventions: Drug: Human fibrinogen concentrate | Arm Label: Group B: apheresis platelets; Type: ACTIVE_COMPARATOR; Interventions: Other: apheresis platelets | Intervention Type: DRUG; Name: Human fibrinogen concentrate; Assigned to Arm(s): Group A: RiaSTAP | Intervention Type: OTHER; Name: apheresis platelets; Assigned to Arm(s): Group B: apheresis platelets

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Brief Summary: Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion (\[MT\] (defined as receiving 10 units or more red blood cells (RBCs) within the first 24 hours). The goal of PROPPR is to improve the basis on which clinicians make decisions about transfusion protocols for massively bleeding patients.

PROPPR is a Resuscitation Outcomes Consortium (ROC) Protocol. ROC is funded by the National Heart, Lung, and Blood Institute (NHLBI), the United States' Department of Defense (DoD) and the Defence Research and Development Canada. PROPPR will be conducted as a Phase III trial at Level I Adult Trauma Centers in North America.


Options:
A: Arm Label: Quarantined FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Arm Label: Methylene blue FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Arm Label: Solvent detergent FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Intervention Type: OTHER; Name: plasma; Assigned to Arm(s): Methylene blue FFP, Quarantined FFP, Solvent detergent FFP
B: Intervention Type: PROCEDURE; Name: central venous catheter application; Assigned to Arm(s): N/A
C: Arm Label: 1:1:1 Blood Transfusion Ratio; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1:1:1 Blood Transfusion Ratio | Arm Label: 1:1:2 Blood Transfusion Ratio; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1:1:2 Blood Transfusion Ratio | Intervention Type: BIOLOGICAL; Name: 1:1:1 Blood Transfusion Ratio; Assigned to Arm(s): 1:1:1 Blood Transfusion Ratio | Intervention Type: BIOLOGICAL; Name: 1:1:2 Blood Transfusion Ratio; Assigned to Arm(s): 1:1:2 Blood Transfusion Ratio
D: Arm Label: No FFP transfusion prior to intervention; Type: EXPERIMENTAL; Interventions: Other: omitting FFP transfusion before an intervention | Arm Label: FFP transfusion prior to intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: omitting FFP transfusion before an intervention; Assigned to Arm(s): No FFP transfusion prior to intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cohort Study to Evaluate Effects of Prophylactic Treatment for Respiratory Syncytial (RS) Virus Infection in Respiratory Tract During Infancy on Subsequent Atopic Asthma in Preterm Infants
Brief Summary: The primary objective of the study is to determine whether the incidence of atopic asthma after three years old may be suppressed in the children who were born as preterm infants and prophylactically treated with palivizumab for respiratory syncytial (RS) virus infections during the infancy.

The secondary objective is to determine whether the incidence of recurrent wheezing after three years old may be suppressed in the children who were born as preterm infants and prophylactically treated with palivizumab for RS virus infections during the infancy.


Options:
A: Arm Label: Treated; Type: N/A; Interventions: N/A | Arm Label: Untreated; Type: N/A; Interventions: N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MEDI8897 50 mg; Type: EXPERIMENTAL; Interventions: Drug: MEDI8897 | Intervention Type: DRUG; Name: MEDI8897; Assigned to Arm(s): MEDI8897 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Palivizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Palivizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Palivizumab; Assigned to Arm(s): Palivizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Treated; Type: N/A; Interventions: N/A | Arm Label: Untreated; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication
Brief Summary: This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily therapy with an inhaled corticosteroid and a second controller medication. Patients will be randomized in a 1:1:1:1 ratio to receive double-blind treatment with subcutaneous lebrikizumab ("highest", "middle", "lowest" dose) or placebo every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. The anticipated time on study treatment is up to 104 weeks. There will be a safety follow-up of 24 weeks after the last dose of study drug for all patients.


Options:
A: Arm Label: Cohort of US adults with severe asthma; Type: N/A; Interventions: N/A
B: Arm Label: Benralizumab 30 mg q.4 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 30 mg q.8 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 30 mg q.4 weeks, Benralizumab 30 mg q.8 weeks | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: lebrikizumab - highest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - lowest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - middle dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - middle dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - lowest dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - highest dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: huMAb OX40L; Type: EXPERIMENTAL; Interventions: Drug: huMAb OX40L | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: huMAb OX40L; Assigned to Arm(s): huMAb OX40L | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication
Brief Summary: This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily therapy with an inhaled corticosteroid and a second controller medication. Patients will be randomized in a 1:1:1:1 ratio to receive double-blind treatment with subcutaneous lebrikizumab ("highest", "middle", "lowest" dose) or placebo every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. The anticipated time on study treatment is up to 104 weeks. There will be a safety follow-up of 24 weeks after the last dose of study drug for all patients.


Options:
A: Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): N/A
B: Arm Label: lebrikizumab - highest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - lowest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - middle dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - highest dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - middle dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - lowest dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: MEDI528 30 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 30 mg | Arm Label: MEDI528 100 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 100 mg | Arm Label: MEDI528 300 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 300 mg | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI528 30 mg; Assigned to Arm(s): MEDI528 30 mg | Intervention Type: BIOLOGICAL; Name: MEDI528 100 mg; Assigned to Arm(s): MEDI528 100 mg | Intervention Type: BIOLOGICAL; Name: MEDI528 300 mg; Assigned to Arm(s): MEDI528 300 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Effectiveness Trial of Early Hemodynamic Support in Patients Demonstrating a Double and Triple Low Combination of Mean Arterial Pressure, and Either End-tidal Anesthetic Concentration or Bispectral Index.
Brief Summary: The objective of this study is to use a decision-support system combined with an electronic anesthesia record to detect double low clinical conditions (Mean Arterial Pressure (MAP) \< 75 mmHg, and Bispectral Index (BIS) \< 45) and generate alerts suggesting hemodynamic support. Specifically, the project will test the hypothesis that providing Double Low alerts reduces 90-day mortality. Secondary outcomes will be the fraction of alerts that generate early clinician responses, subsequent changes in MAP and hospital length of stay.


Options:
A: Arm Label: Intervention group; Type: N/A; Interventions: Behavioral: reminders | Arm Label: current practice group; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: reminders; Assigned to Arm(s): Intervention group
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: STOPP Criteria Decision Support Content | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: STOPP Criteria Decision Support Content; Assigned to Arm(s): Intervention
C: Intervention Type: PROCEDURE; Name: Computer-Assisted diagnostic Decision Support; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: written diagnostic guidelines; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: electronic therapeutic reminders; Assigned to Arm(s): N/A
D: Arm Label: Notification Group; Type: EXPERIMENTAL; Interventions: Behavioral: Notification Group | Arm Label: No Notification; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Notification Group; Assigned to Arm(s): Notification Group

Answer: D